Antidilutive Securities [Axis] Share capital Warrants [Member] Option [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Distribution Agreement Placement agency agreement Warrants One [Member] Equity Components [Axis] Common Stock Additional Paid-In Capital Accumulated Deficit Accumulated Other Comprehensive Loss Management Consultancy Agreement [Member] Related Party [Axis] Management Consulting Company [Member] Note Purchase Agreement [Member] Investor [Member] Long-term Debt, Type [Axis] Secured Note [Member] Investor Note #1 [Member] Investor Note #2 [Member] Placement agent Kingswood Accumulated Other Comprehensive Income Document and Entity Information: Entity Registrant Name Document Type Document Period End Date Amendment Flag Entity Central Index Key Current Fiscal Year End Date Entity Common Stock, Shares Outstanding Entity Public Float Entity Filer Category Entity Emerging Growth Company Entity Small Business Entity Shell Company Entity Current Reporting Status Entity Voluntary Filers Entity Well-known Seasoned Issuer Entity Interactive Data Current Entity File Number Entity Incorporation, State or Country Code Document Fiscal Year Focus Document Fiscal Period Focus Statement of Financial Position [Abstract] ASSETS Current assets: Cash Prepaid expenses and other receivables Inventory (raw materials) Total current assets Other assets: Property and equipment, net of accumulated depreciation Intangible assets, net of accumulated amortization Total other assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts Payable Liability due to related parties Other Liabilities and accrued expenses Notes payable, net of unamortized discount Deferred revenue Total current liabilities Non-current portion of notes payable, net of unamortized discount Non-current portion of deferred revenue Total non-current liabilities Total liabilities Commitments and contingencies Stockholders' equity (deficit): Series A convertible preferred stock, $0.001 par value, 200,000 shares authorized; 0 shares issued and outstanding at September 30, 2020 and March 31, 2020 Common stock, $0.001 par value, 42,000,000 shares authorized and 21,282,133 and 20,850,848 shares issued and outstanding at September 30, 2020 and March 31, 2020, respectively Additional paid in capital Accumulated deficit Accumulated other comprehensive loss Total stockholders' equity/ (deficit) Total liabilities and stockholders' equity Preferred stock, par value (in dollars per share) Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value per share Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue: Total revenues Operating expenses: Research and development General and administrative Total operating expenses Loss from operations Interest (expense) income Net loss Other comprehensive loss: Foreign currency translation adjustment Comprehensive loss Loss per share: Basic and diluted Weighted average number of shares outstanding Statement of Cash Flows [Abstract] Cash Flows From Operating Activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and Amortization Accretion of debt discount Stock Based Compensation Changes in assets and liabilities: Prepaid expenses and other receivables Inventory Accounts payable Liability due to related party Other liabilities and accrued expenses Net cash used in operating activities Cash Flows from Investing Activities: Capitalized patent costs Purchase of property and equipment Net cash (used in) provided by investing activities Cash Flows from Financing Activities: Costs incurred in relation to equity financing Commission paid on note payable Proceeds from issuance of notes Proceeds from issuance of common stock in relation to equity financing Proceeds from warrant exercise Repayments of note payable Net cash provided by financing activities Net (decrease) increase in cash Effect of exchange rate changes on cash Cash at beginning of period Cash at end of period Supplemental disclosure of non-cash financing activities: Prepayment of equity compensation Statement [Table] Statement [Line Items] Beginning Balance, Shares Beginning Balance, Amount Issuance of common shares, net of offering costs, Shares Issuance of common shares, net of offering costs, Amount Exercise of warrants, Shares Exercise of warrants, Amount Restricted shares issued as stock- based compensation to consultants and investor relations, Shares Restricted shares issued as stock- based compensation to consultants and investor relations, Amount Foreign currency translation adjustment Ending Balance, Shares Ending Balance, Amount Disclosure Text Block [Abstract] ORGANIZATION AND PRINCIPAL ACTIVITIES Basis of Presentation Licensing Agreement Related Party Transactions Equity [Abstract] STOCKHOLDERS' EQUITY Debt Disclosure [Abstract] NOTES PAYABLE Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] OTHER ITEMS Basis of presentation Changes to significant accounting policies Recently adopted accounting pronouncements Table Text Block Supplement [Abstract] Schedule of Related Party Transactions Schedule of earnings (loss) per share Cash available on hand Unsecured senior credit facility description Proceeds from common stock sold Licensing Agreement Details Narrative Non-refundable, upfront cash payment Deferred revenue Related Party Transactions [Abstract] Liability due to related party, beginning of period Amount invoiced by Pharma to DDL, NM and TCL Amounts invoiced by DDL to Pharma Amounts paid by DDL to Pharma Foreign exchange differences Liability due to related party, end of the period Net loss attributable to common stockholders Weighted average basic and diluted shares outstanding Basic and diluted loss per share Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Reverse stock split Conversion of common stock Common stock converted into convertible Preferred Stock Conversion basis Cancellation of common stock Anti-dilutive common stock Number of common stock sold Related cost Proceeds from warrants Placement agent commissions Warrants exercised Warrants exercisable Warrant Outstanding Proceeds from sale of common stock and warrants Number of warrants purchased Principal amount Amount paid in cash Legal fees Original issue discount Purchase Price Term Monitoring fee percentage Interest rate Accretion Proceeds from note payable Subsequent Event Type [Axis] Stock compensation expense Related party expenses Assets, Current Assets Liabilities, Current Liabilities, Noncurrent Liabilities Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Operating Expenses Operating Income (Loss) Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Inventories Net Cash Provided by (Used in) Operating Activities Payments to Acquire Intangible Assets Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Foreign exchange differences [Default Label] CommissionPaidOnNotePayable Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Shares, Issued Stockholders' Equity Attributable to Parent OCI, Foreign Currency Transaction and Translation Gain (Loss), Arising During Period, Tax Deferred Revenue Related Party Transaction, Due from (to) Related Party